Pancreatic Cancer Research

ResearcherShanghai Medical College of Fudan UniversityActive in the last 2 years

Hongrui Fan

Matched on OpenAlex author ID A5074696551. Sources: OpenAlex.

Their work

Papers
5 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
9
Papers, trials and grants by year

2023: 1 paper · 2024: none · 2025: 2 papers · 2026: 2 papers

Papers 5

  1. Mitocytosis-inducing nanoparticles alleviate gemcitabine resistance via dual disruption of pyrimidine synthesis and redox homeostasis in pancreatic ductal aden… First author DOI 10.1016/j.biomaterials.2025.123630↗
  2. Size switchable nanomodulator achieving ratio-precise dual-drug codelivery for synergistic glutamine metabolism modulation in pancreatic cancer. Co-author DOI 10.1016/j.biomaterials.2026.124406↗
  3. Cascade-Targeted Nanoparticles for Enhanced Gemcitabine Delivery and Adenosine Metabolism Modulation to Overcome Treatment Resistance in Pancreatic Cancer. Co-author DOI 10.1002/advs.202507118↗
  4. Transcytosis-Triggering Nanoparticles for Overcoming Stromal Barriers and Reversing Immunosuppression in Pancreatic Cancer Combinatorial Therapy. Co-author DOI 10.1021/acs.nanolett.4c06372↗
  5. Gradient tumor microenvironment-promoted penetrating micelles for hypoxia relief and immunosuppression reversion in pancreatic cancer treatment. Co-author DOI 10.1016/j.actbio.2023.05.047↗

Closest collaborators

The 9 strongest of 9 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Haolin Song · 5 shared papers, 2023–2026 · strength 1.14
  2. Chen Jiang · 5 shared papers, 2023–2026 · strength 1.14
  3. Yu Wang · 3 shared papers, 2025–2026 · strength 0.74
  4. Tao Sun · 3 shared papers, 2023–2026 · strength 0.64
  5. Qinjun Chen · 3 shared papers, 2023–2026 · strength 0.64
  6. Shilin Zhang · 3 shared papers, 2023–2026 · strength 0.61
  7. Hongyi Chen · 2 shared papers, 2023–2025 · strength 0.37
  8. Chufeng Li · 2 shared papers, 2023–2025 · strength 0.37
  9. Yifan Luo · 1 shared paper, 2023 · strength 0.14

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.